Bispecific antibodies and their applications
Recombinant bispecific antibodies with CD3 and B7H6 binding activity address the limitations of current B7H6-targeting therapies by providing strong binding, long half-life, and selective tumor localization with reduced systemic toxicity.
Patent Information
- Application Number
- JP2023555735
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-07
- Filing Date
- 2022-06-22
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2042-06-22
AI Technical Summary
Current bispecific antibodies targeting B7H6 for tumor therapy have limitations such as short half-life and systemic toxicity, and there is a need for highly targeted antibodies that can selectively localize to tumor cells without activating lymphocytes systemically.
Development of recombinant bispecific antibodies with specific CD3 and B7H6 binding activity, utilizing CDR sequences with high affinity, to form an immune synapse with tumor cells, activating lymphocytes and enhancing antitumor activity.
The recombinant antibodies exhibit strong in vivo and in vitro binding activity, long half-life, and significant antitumor effects with selective localization to tumor cells, reducing systemic activation and toxicity.
Smart Images

Figure 2024542899000001 
Figure 2024542899000002 
Figure 2024542899000003
Abstract
Description
[Technical field]
[0001] The present invention belongs to the field of biomedicine, specifically relates to bispecific antibodies and their applications, more specifically relates to recombinant antibodies, immune cells, nucleic acids, expression vectors, recombinant cells, compositions, the use of said materials in the preparation of drugs, and kits. [Background technology]
[0002] A bispecific antibody is an antibody that specifically binds to two antigen sites simultaneously. Bispecific antibodies for tumor therapy can be classified into three types according to their mechanism of action: redirection of effector cells, immunomodulation, and targeting of dual binding of tumor cell receptors. Here, antibodies for redirection function account for the majority of them, and the two antibodies for tumor therapy currently on the market are also based on T cell redirection. Depending on the properties of bispecific antibodies, they can also be used in other therapeutic systems, such as dual immunomodulation and targeting two molecules of the same cell membrane.
[0003] B7H6 is a type I transmembrane protein belonging to the B7 family that contains two immunoglobulin domains. B7H6 is also a ligand for the NK cell activating receptor NKp30. B7H6 is expressed on many tumor cells, but B7H6 mRNA has not been detected in human normal tissues and healthy peripheral blood mononuclear cells. In an inflammatory environment, some proinflammatory cytokines, such as IL-1β and TNF, can stimulate CD14+ and CD16+ monocytes and neutrophils to upregulate B7H6 expression. B7H6 has a broad tumor expression profile, including leukemia, lymphoma, colorectal cancer, non-small cell lung cancer, breast cancer, ovarian cancer, gastric cancer and liver cancer. B7H6 expression is also associated with metastasis of some cancers, but the role of B7H6 in most tumors is currently unknown. Currently, B7H6 is expressed in many tumors, but there are not many tumor therapeutic approaches against this molecule. The researchers developed a bispecific antibody against B7H6 in a construction format known as BiTE, and determined that because this format does not contain the constant regions of natural antibodies, the molecule has a short half-life in the body, severely limiting its use.
[0004] Among T cell redirection-based bispecific antibodies, CD3 is a very important target. Unlike immune checkpoint inhibitor antibodies, CD3-associated bispecific antibodies can mediate T cell activation beyond TCR and peptide (major histocompatibility complex (pMHC)), but the molecular action process in the synapse is very similar to traditional TCR-pMHC interaction. The activity of bispecific antibodies is affected by CD3 affinity, and CD3 high affinity bispecific antibodies have better killing effect in in vitro experiments, but have fatal cytokine release syndrome toxicity in vivo, which is very similar to chimeric antigen receptor (CAR) T cell toxicity. At the same time, studies have found that very low affinity CD3 antibody sequences can also effectively stimulate T cell activation after the construction of bispecific antibodies. When the affinity of CD3 antibodies is in the appropriate range (200 ± 78 nM) and the affinity of tumor target-associated antibodies is high, bispecific antibodies can encourage T cells to selectively localize in tumors rather than circulating in the periphery, avoiding systemic activation. Therefore, the development of highly targeted bispecific antibodies is of great value to the prevention and treatment of tumors. Summary of the Invention [Problem to be solved by the invention]
[0005] This application is based on the inventor's discovery and knowledge of the following facts and problems. In the present invention, the inventors have carried out various combinations and screenings of CD3 and B7H6 antigen-binding fragments to design a recombinant bispecific antibody, which can specifically bind to CD3 and specifically bind to B7H6, and then bring the B7H6 molecule close to tumor cells in a targeted manner. CD3 can be bound to the B7H6 molecule on tumor cells by binding to the B7H6 molecule on the tumor cells. + lymphocytes form immune synapses with tumor cells, which activates the lymphocytes and induces the expression of B7H6 + The recombinant bispecific antibody has high CD3 and B7H6 binding activity as well as high anti-tumor activity. [Means for solving the problem]
[0006] Therefore, in a first aspect of the present invention, the present invention proposes a recombinant antibody. According to an embodiment of the present invention, the recombinant antibody comprises a CDR sequence selected from at least one of SEQ ID NOs: 1-6, and B7H6 antibody variable region CDR sequences: SEQ ID NOs: 7-12, or an amino acid sequence having at least 95% identity thereto. The recombinant antibody according to an embodiment of the present invention effectively binds to CD3 and B7H6, has strong in vivo and in vitro binding activity, has a long in vivo half-life, and has a significant anti-tumor effect.
[0007] RASQDIRNYLN(SEQ ID NO:1). YTSRLES(SEQ ID NO:2). QQGNTLPWT(SEQ ID NO:3). GYTMN (SEQ ID NO:4). LINPYKGVSTYNQKFKD(SEQ ID NO:5). SGYYGDSDWYFDV (SEQ ID NO: 6). KASQSVDYDGDSYMN(SEQ ID NO:7). AASTLHS (SEQ ID NO:8). QQSKEDPRT(SEQ ID NO:9). DYNMD(SEQ ID NO:10). DINPNNGGTLYNQKFRG(SEQ ID NO:11). SEVFYGNYADY (SEQ ID NO:12).
[0008] In a second aspect of the present invention, the present invention provides a recombinant antibody, which according to an embodiment of the present invention has the amino acid sequence shown in SEQ ID NO: 49 and 63. The recombinant antibody according to an embodiment of the present invention effectively binds to CD3 and B7H6, has strong in vivo and in vitro binding activity, a long in vivo half-life, and has a significant anti-tumor effect.
[0009] MDIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIKGGGGSGGGSGGGSEGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYGDSDWYFDVWGQGTLVTVSSEPKSCDKTHTCPPCPPAPEAAGGPSVFLFPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:49). DIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSYMNWYLQKPGQPPQLLIYAASTLHSGIPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWIGDINPNNGGTLYNQKFRGRVTLTVDTSISTAYMELSRLRSDDTAVYCARSEVGYNYADYWGQGTT VTVSSEPKSCDKTHTCPPCPAPEAAGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPGK(SEQ ID NO:63)。
[0010] In a third aspect of the present invention, the present invention provides a nucleic acid, which according to an embodiment of the present invention encodes a recombinant antibody according to the first aspect. The recombinant antibody encoded by the nucleic acid according to an embodiment of the present invention effectively binds to CD3 and B7H6, has strong in vivo and in vitro binding activity, a long in vivo half-life, and has a significant anti-tumor effect.
[0011] In a fourth aspect of the present invention, the present invention proposes an expression vector. According to an embodiment of the present invention, said expression vector carries a nucleic acid molecule according to the third aspect. The expression vector may comprise a selectable control sequence, which is operably linked to said nucleic acid molecule, wherein said control sequence is one or more control sequences capable of directing the expression of the nucleic acid molecule in a host. The expression vector according to an embodiment of the present invention can efficiently and abundantly express said recombinant antibody in a suitable host cell, and can be effectively used for the specific treatment or prevention of tumors, particularly tumors expressing B7H6.
[0012] In a fifth aspect of the present invention, the present invention proposes a recombinant cell. According to an embodiment of the present invention, said recombinant cell carries a nucleic acid molecule according to the third aspect, an expression vector according to the fourth aspect or a recombinant antibody according to the first aspect. Said recombinant cell is obtained by transfection or transformation of said expression vector. According to an embodiment of the present invention, said recombinant cell is capable of efficiently and abundantly expressing said recombinant antibody under suitable conditions, and said recombinant cell can be effectively used for specific treatment or prevention of tumors, in particular tumors expressing B7H6.
[0013] In the sixth aspect of the present invention, the present invention proposes a composition. According to an embodiment of the present invention, the composition comprises a recombinant antibody according to the first or second aspect, a nucleic acid molecule according to the third aspect, an expression vector according to the fourth aspect, or a recombinant cell according to the fifth aspect. As described above, the recombinant antibody according to the embodiment of the present invention can effectively bind to CD3 or B7H6 protein molecule, and can specifically recognize tumor cells with high expression of B7H6, so as to induce T cells to selectively localize in the tumor instead of circulating in the periphery, and avoid systemic activation, and the drug comprising the recombinant antibody also has a significant effect of treating or preventing tumors expressing B7H6, and its safety is higher and side effects are smaller.
[0014] In the seventh aspect of the present invention, the present invention proposes the use of the recombinant antibody according to the first or second aspect, the nucleic acid molecule according to the third aspect, the expression vector according to the fourth aspect, the recombinant cell according to the fifth aspect or the composition according to the sixth aspect in the preparation of a drug. According to an embodiment of the present invention, the drug is used for treating or preventing tumors. As mentioned above, the recombinant antibody according to the embodiment of the present invention can effectively bind to CD3 and B7H6 proteins, and specifically recognize tumor cells with high expression of B7H6, and the drug prepared using the recombinant antibody and a series of corresponding substances also has a significant effect of treating or preventing tumors expressing B7H6, and its safety is higher and side effects are smaller.
[0015] In the eighth aspect of the present invention, the present invention proposes a drug. According to an embodiment of the present invention, the drug includes the recombinant antibody according to the first or second aspect, the nucleic acid molecule according to the third aspect, the expression vector according to the fourth aspect, the recombinant cell according to the fifth aspect, or the composition according to the sixth aspect, and is used for treating and preventing cancer. As mentioned above, the recombinant antibody according to the embodiment of the present invention can effectively bind to CD3 and B7H6 protein, and specifically recognize tumor cells with high expression of B7H6, and the drug prepared using the recombinant antibody and a series of corresponding substances also has a significant effect of treating or preventing tumors expressing B7H6, and its safety is higher and side effects are smaller.
[0016] In a ninth aspect of the present invention, the present invention proposes a kit. According to an embodiment of the present invention, the kit comprises a recombinant antibody according to the first or second aspect. The antibody according to the embodiment of the present invention can effectively bind to CD3 and B7H6 protein molecules, and can specifically recognize highly specific tumor cells expressing B7H6, so that the recombinant antibody can be used to manufacture a kit for diagnosing or detecting at least one of rectal cancer, non-small cell lung cancer, breast cancer and liver cancer. The kit can be used for scientific research, such as qualitative or quantitative detection of CD3 and / or B7H6 protein molecules in biological samples.
[0017] Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. [Brief description of the drawings]
[0018] The above and / or additional aspects and advantages of the present invention will become apparent and will be readily understood from the following detailed description of the embodiments taken in conjunction with the accompanying drawings. [Figure 1] FIG. 1 is a schematic diagram of the structure of a recombinant bispecific antibody according to an embodiment of the present invention. [Figure 2A]FIG. 1 shows the results of a binding analysis between a CD3×B7H6 recombinant bispecific antibody according to an embodiment of the present invention and human B7H6 protein. [Figure 2B] FIG. 1 shows the results of a binding analysis between the CD3×B7H6 recombinant bispecific antibody according to an embodiment of the present invention and human CD3 protein. [Figure 2C] 1 is a graph showing the ELISA detection results of the CD3×B7H6 recombinant bispecific antibody according to an embodiment of the present invention and B7H6 and human CD3 biantigens. [Figure 3A] 1 is a graph showing the analytical results of an in vitro cytotoxicity experiment of CD3×B7H6 recombinant bispecific antibodies and T cells according to an embodiment of the present invention against HCT-15 cells. [Figure 3B] 1 is a graph showing the analytical results of an in vitro cytotoxicity experiment of CD3×B7H6 recombinant bispecific antibodies and T cells according to an embodiment of the present invention against LoVo cells. [Figure 3C] 1 is a graph showing the results of an in vitro cytotoxicity experiment of CD3×B7H6 recombinant bispecific antibodies and T cells according to an embodiment of the present invention against Hep G2 cells. [Figure 3D] 1 is a graph showing the results of an in vitro cytotoxicity experiment of CD3×B7H6 recombinant bispecific antibodies and T cells according to an embodiment of the present invention against SK-BR-3 cells. [Figure 4A] FIG. 13 is a graph showing the analytical results of chemiluminescence values detected after mixing T cells according to an embodiment of the present invention with Ho8910 cells overexpressing luciferase, adding CD3×B7H6 recombinant bispecific antibody molecules at gradient concentrations, and reacting with a substrate after 24 hours. [Figure 4B] FIG. 13 is a graph showing the analytical results of chemiluminescence values detected after mixing T cells according to an embodiment of the present invention with K562 cells overexpressing luciferase, adding CD3×B7H6 bispecific antibody molecules at gradient concentrations, and reacting with a substrate after 24 hours. [Figure 5A] FIG. 1 is a graph showing the effect of CD3×B7H6 recombinant bispecific antibody molecule on T cell proliferation in the presence of HCT-15 cells according to an embodiment of the present invention. [Figure 5B]1 is a statistical analysis chart of the effect of CD3×B7H6 recombinant bispecific antibody molecule on T cell proliferation in the presence of HCT-15 cells according to an embodiment of the present invention. [Figure 6A] 1 is a graph showing the effect of a CD3×B7H6 recombinant bispecific antibody molecule on CD4+ and CD8+ T cell activation in the presence of HCT-15 cells according to an embodiment of the present invention. [Figure 6B] FIG. 13 is a graph showing the effect of CD3×B7H6 recombinant bispecific antibody molecule on the level of CD4+ and CD8+ T cell degranulation in the presence of HCT-15 cells according to an embodiment of the present invention. [Figure 7A] 1 is a graph showing the effect of CD3×B7H6 recombinant bispecific antibody molecule on IFN-γ secretion by T cells in the presence of HCT-15 cells according to an embodiment of the present invention. [Figure 7B] FIG. 13 is a graph showing the effect of CD3×B7H6 recombinant bispecific antibody molecule on IL-2 secretion by T cells in the presence of HCT-15 cells according to an embodiment of the present invention. [Figure 7C] 1 is a graph showing the effect of CD3×B7H6 recombinant bispecific antibody molecule on IL-10 secretion by T cells in the presence of HCT-15 cells according to an embodiment of the present invention. [Figure 7D] 1 is a graph showing the effect of CD3×B7H6 recombinant bispecific antibody molecule on IL-17A secretion by T cells in the presence of HCT-15 cells according to an embodiment of the present invention. [Figure 8] 1 is a graph showing the results of the in vivo antitumor activity of the CD3×B7H6 recombinant bispecific antibody molecule according to an embodiment of the present invention on HCT-15 cells. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0019] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, the embodiments of the present invention will be described in detail, and examples of the embodiments are shown in the drawings. The embodiments described below with reference to the drawings are illustrative and are intended to interpret the present invention, but should not be understood as limiting the present invention.
[0020] It should be noted that the terms "first", "second" and the like are merely for explanatory purposes and cannot be considered as indicating or implying relative importance or implying the number of technical features. Thus, a feature defined as "first" or "second" can be explicitly or implicitly defined to include at least one of the feature, and in the description of the invention, the concept of "plurality" is at least two, e.g., two or three, unless otherwise clearly and specifically limited.
[0021] Recombinant antibodies In a first aspect of the present invention, the present invention provides a recombinant antibody. According to some specific embodiments of the present invention, the recombinant antibody comprises a first antigen-binding region that binds to CD3 and a second antigen-binding region that specifically binds to B7H6. The recombinant antibody according to the embodiments of the present invention can effectively bind to CD3 in T cells and B7H6 in tumor cells, has strong in vivo and in vitro binding activity, has a long in vivo half-life, and can simultaneously bind to T cells and tumor cells, allowing the two cells to form a cell synapse, thus providing a significant anti-tumor effect.
[0022] According to some specific embodiments of the present invention, the above recombinant antibody may further include at least one of the following additional technical features:
[0023] According to some specific embodiments of the present invention, the recombinant antibody comprises a CDR sequence selected from at least one of SEQ ID NOs: 1-6 and B7H6 antibody variable region CDR sequences: SEQ ID NOs: 7-12, or an amino acid sequence having at least 95% identity thereto. The recombinant antibody according to the embodiments of the present invention effectively binds to CD3 and B7H6, has strong in vivo and in vitro binding activity, long in vivo half-life, and significant anti-tumor effect.
[0024] RASQDIRNYLN(SEQ ID NO:1). YTSRLES(SEQ ID NO:2). QQGNTLPWT(SEQ ID NO:3). GYTMN (SEQ ID NO:4). LINPYKGVSTYNQKFKD(SEQ ID NO:5). SGYYGDSDWYFDV (SEQ ID NO: 6). KASQSVDYDGDSYMN(SEQ ID NO:7). AASTLHS (SEQ ID NO:8). QQSKEDPRT(SEQ ID NO:9). DYNMD(SEQ ID NO:10). DINPNNGGTLYNQKFRG(SEQ ID NO:11). SEVFYGNYADY (SEQ ID NO:12).
[0025] According to some specific embodiments of the present invention, the variable region of the CD3 antibody comprises a light chain variable region shown in SEQ ID NO:13, a heavy chain variable region shown in SEQ ID NO:14, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the amino acid sequences shown in SEQ ID NO:13 and SEQ ID NO:14.
[0026] MDIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIK(SEQ ID NO:13). EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSS(SEQ ID NO:14).
[0027] According to some specific embodiments of the present invention, the antibody comprises a variable region of the B7H6 antibody, the variable region of the B7H6 antibody having a light chain variable region having an amino acid sequence shown in SEQ ID NO:20 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO:23, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the amino acid sequences shown in SEQ ID NO:20 and SEQ ID NO:23.
[0028] DIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSYMNWYLQKPGQPPQLLIYAASTLHSGIPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSKEDPRTFGQGTKLEIK(SEQ ID NO:20). EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWIGDINPNNGGTLYNQKFRGRVTLTVDTSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSS(SEQ ID NO:23).
[0029] According to some specific embodiments of the present invention, the variable region of the B7H6 antibody has a light chain variable region having an amino acid sequence shown in SEQ ID NO:16 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO:22, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the amino acid sequences shown in SEQ ID NO:16 and SEQ ID NO:22.
[0030] According to some specific embodiments of the present invention, the variable region of the B7H6 antibody has a light chain variable region having an amino acid sequence shown in SEQ ID NO:16 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO:23, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the amino acid sequences shown in SEQ ID NO:16 and SEQ ID NO:23.
[0031] According to some specific embodiments of the present invention, the variable region of the B7H6 antibody has a light chain variable region having an amino acid sequence shown in SEQ ID NO:16 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO:24, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the amino acid sequences shown in SEQ ID NO:16 and SEQ ID NO:24.
[0032] According to some specific embodiments of the present invention, the variable region of the B7H6 antibody has a light chain variable region having an amino acid sequence shown in SEQ ID NO:16 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO:25, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the amino acid sequences shown in SEQ ID NO:16 and SEQ ID NO:25.
[0033] According to some specific embodiments of the present invention, the variable region of the B7H6 antibody has a light chain variable region having an amino acid sequence shown in SEQ ID NO:17 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO:22, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the amino acid sequences shown in SEQ ID NO:17 and SEQ ID NO:22.
[0034] According to some specific embodiments of the present invention, the variable region of the B7H6 antibody has a light chain variable region having an amino acid sequence shown in SEQ ID NO:17 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO:23, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the amino acid sequences shown in SEQ ID NO:17 and SEQ ID NO:23.
[0035] According to some specific embodiments of the present invention, the variable region of the B7H6 antibody has a light chain variable region having an amino acid sequence shown in SEQ ID NO:17 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO:24, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the amino acid sequences shown in SEQ ID NO:17 and SEQ ID NO:24.
[0036] According to some specific embodiments of the present invention, the variable region of the B7H6 antibody has a light chain variable region having an amino acid sequence shown in SEQ ID NO:17 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO:25, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the amino acid sequences shown in SEQ ID NO:17 and SEQ ID NO:25.
[0037] According to some specific embodiments of the present invention, the variable region of the B7H6 antibody has a light chain variable region having an amino acid sequence shown in SEQ ID NO:19 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO:22, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the amino acid sequences shown in SEQ ID NO:19 and SEQ ID NO:22.
[0038] According to some specific embodiments of the present invention, the variable region of the B7H6 antibody has a light chain variable region having an amino acid sequence shown in SEQ ID NO:19 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO:23, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the amino acid sequences shown in SEQ ID NO:19 and SEQ ID NO:23.
[0039] According to some specific embodiments of the present invention, the variable region of the B7H6 antibody has a light chain variable region having an amino acid sequence shown in SEQ ID NO:19 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO:24, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the amino acid sequences shown in SEQ ID NO:19 and SEQ ID NO:24.
[0040] According to some specific embodiments of the present invention, the variable region of the B7H6 antibody has a light chain variable region having an amino acid sequence shown in SEQ ID NO:19 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO:25, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the amino acid sequences shown in SEQ ID NO:19 and SEQ ID NO:25.
[0041] According to some specific embodiments of the present invention, the variable region of the B7H6 antibody has a light chain variable region having an amino acid sequence shown in SEQ ID NO:20 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO:22, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the amino acid sequences shown in SEQ ID NO:20 and SEQ ID NO:22.
[0042] According to some specific embodiments of the present invention, the variable region of the B7H6 antibody has a light chain variable region having an amino acid sequence shown in SEQ ID NO:20 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO:24, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the amino acid sequences shown in SEQ ID NO:20 and SEQ ID NO:24.
[0043] According to some specific embodiments of the present invention, the variable region of the B7H6 antibody has a light chain variable region having an amino acid sequence shown in SEQ ID NO:20 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO:25, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the amino acid sequences shown in SEQ ID NO:20 and SEQ ID NO:25.
[0044] According to some specific embodiments of the present invention, the variable region of the B7H6 antibody has a light chain variable region having an amino acid sequence shown in SEQ ID NO:15 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO:26, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the amino acid sequences shown in SEQ ID NO:15 and SEQ ID NO:26.
[0045] According to some specific embodiments of the present invention, the variable region of the B7H6 antibody has a light chain variable region having an amino acid sequence shown in SEQ ID NO:18 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO:21, or an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to the amino acid sequences shown in SEQ ID NO:18 and SEQ ID NO:21.
[0046] DIVLTQSPVSLAVPLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGIPVRFSGSGSGTDFTLNIHPVEEEDAASYYCQQSKEDPRTFGGGTKLEIK(SEQ ID NO:15). DIVLTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGVPDRFSGSGSGTFTLTISSLQAEDVAVYYCQQSKEDPRTFGQGTKLEIK(SEQ ID NO:16). DIVLTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGIPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPRTFGQGTKLEIK(SEQ ID NO:17). DIVLTQSPVSLAVPLGQRATISCKASQSVDYDADSYMNWYQQKPGQPPKLLIYAASTLHSGIPVRFSGSGSGTDFTLNIHPVEEEDAASYYCQQSKEDPRTFGGGTKLEIK(SEQ ID NO:18)。 DIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSYMNWYLQKPGQPPQLLIYAASTLHSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSKEDPRTFGQGTKLEIK(SEQ ID NO:19)。 EVLLQQSGPEVVKPGASVKITCKASGYTFTDYNMDWVKQSHGKSLEWIGDINPNNGGTLYNQKFRGRVTLIVDKSSSTAYMELRSLTSDDTAVYYCARSEVFYGNYADYWGQGTTLTVSS(SEQ ID NO:21)。 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWMGDINPNNGGTLYNQKFRGRVTMTVDTSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSS(SEQ ID NO:22)。 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWIGDINPNNGGTLYNQKFRGRVTLTVDKSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSS(SEQ ID NO:24)。 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGKGLEWIGDINPNNGGTLYNQKFRGRVTLTVDKSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSS(SEQ ID NO:25)。 EVLLQQSGPEVVKPGASVKITCKASGYTFTDYNMDWVKQSHGKSLEWIGDINPNNAGTLYNQKFRGRVTLIVDKSSSTAYMELRSLTSDDTAVYYCARSEVFYGNYADYWGQGTTLTVSS(SEQ ID NO:26).
[0047] According to some specific embodiments of the invention, the compound further comprises a connecting peptide.
[0048] According to some specific embodiments of the invention, the connecting peptide has the amino acid sequence shown in SEQ ID NO:46. GGGGSGGGGSGGGGS (SEQ ID NO:46).
[0049] According to some specific embodiments of the present invention, the N-terminus of the connecting peptide is linked to the C-terminus of the light chain variable region of the CD3 antibody, and the C-terminus of the connecting peptide is linked to the N-terminus of the heavy chain variable region of the CD3 antibody.
[0050] According to some specific embodiments of the present invention, the N-terminus of the connecting peptide is linked to the C-terminus of the B7H6 light chain variable region, and the C-terminus of the connecting peptide is linked to the N-terminus of the B7H6 heavy chain variable region.
[0051] According to some specific embodiments of the present invention, the antibody further comprises a first Fc region and a second Fc region, at least a portion of which is derived from at least one of a mouse-derived antibody, a human-derived antibody, a primate-derived antibody, or a variant thereof.
[0052] According to some specific embodiments of the present invention, at least a portion of the first Fc region and the second Fc region are derived from human IgG or a variant thereof.
[0053] According to some specific embodiments of the present invention, at least a portion of the first Fc region and the second Fc region is derived from human IgG1 or a variant thereof.
[0054] According to some specific embodiments of the present invention, the first Fc region has at least one of an S384C mutation and a T396W mutation compared to a wild-type IgG1 Fc region.
[0055] According to some specific embodiments of the present invention, the second Fc region has at least one of the following mutations compared to a wild-type IgG1 Fc region: Y380C, T397S, L399A, and Y408V.
[0056] According to some specific embodiments of the present invention, the first antibody Fc region has the amino acid sequence shown in SEQ ID NO:47, and the second antibody Fc region has the amino acid sequence shown in SEQ ID NO:48.
[0057] EPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALAPIE KTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:47). EPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALAPIE KTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:48).
[0058] In a second aspect of the present invention, the present invention provides a recombinant antibody, which according to an embodiment of the present invention has the amino acid sequence shown in SEQ ID NO: 49 and 63. The recombinant antibody according to an embodiment of the present invention can effectively bind to CD3 and B7H6, has strong in vivo and in vitro binding activity, a long in vivo half-life, and a significant anti-tumor effect.
[0059] MDIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIKGGGGSGGGGSGG GGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTL VTVSSEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:49). DIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSYMNWYLQKPGQPPQLLIYAASTLHSGIPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSKEDPRTFGQGTKLEIKGGGGGSGGGG SGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWIGDINPNNGGTLYNQKFRGRVTLTVDTSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTT VTVSSEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:63).
[0060] Preventive or therapeutic compositions In a third aspect of the present invention, the present invention provides a nucleic acid, which encodes the above-mentioned recombinant antibody. The recombinant antibody encoded by the nucleic acid according to some specific embodiments of the present invention can effectively bind to CD3 and B7H6, has strong in vivo and in vitro binding activity, long in vivo half-life, and significant anti-tumor effect.
[0061] According to some specific embodiments of the invention, the nucleic acid has at least one of the nucleotide sequences set forth in SEQ ID NO:69 and SEQ ID NO:70-87.
[0062] Nucleotide sequences encoding CD3 antibodies
[0063] Nucleotide sequence encoding the B7H6-1 antibody
[0064] Nucleotide sequence encoding the B7H6-2 antibody
[0065] Nucleotide sequence encoding the B7H6-3 antibody
[0066] Nucleotide sequence encoding the B7H6-4 antibody
[0067] Nucleotide sequence encoding the B7H6-5 antibody
[0068] Nucleotide sequence encoding the B7H6-6 antibody
[0069] Nucleotide sequence encoding the B7H6-7 antibody
[0070] Nucleotide sequence encoding the B7H6-8 antibody
[0071] Nucleotide sequence encoding the B7H6-9 antibody
[0072] Nucleotide sequence encoding the B7H6-10 antibody
[0073] Nucleotide sequence encoding the B7H6-11 antibody
[0074] Nucleotide sequence encoding the B7H6-12 antibody
[0075] Nucleotide sequence encoding the B7H6-13 antibody
[0076] Nucleotide sequence encoding the B7H6-14 antibody
[0077] Nucleotide sequence encoding B7H6-15
[0078] Nucleotide sequence encoding the B7H6-16 antibody
[0079] Nucleotide sequence encoding the B7H6-17 antibody
[0080] Nucleotide sequence encoding the B7H6-18 antibody
[0081] It should be understood by those skilled in the art that the nucleic acids referred to in the present specification and claims may actually include either or both of the complementary strands. For convenience, the present specification and claims often show only one strand, but in reality the other strand is also shown. Also, the nucleic acid sequences in the present application include DNA or RNA forms, and the disclosure of one means the disclosure of the other.
[0082] In a fourth aspect of the present invention, the present invention proposes an expression vector, which carries the nucleic acid molecule as described above. The expression vector may include a selectable control sequence, which is operably linked to the nucleic acid molecule. The control sequence is one or more control sequences capable of directing the expression of the nucleic acid molecule in a host. In some specific embodiments of the present invention, the proposed expression vector can efficiently express the recombinant antibody in a suitable host cell, and can be effectively used for the specific treatment or prevention of tumors, especially tumors expressing B7H6.
[0083] In a fifth aspect of the present invention, the present invention proposes a recombinant cell, which carries a nucleic acid molecule according to the third aspect, an expression vector according to the fourth aspect or a recombinant antibody according to the first or second aspect. The recombinant cell is obtained by transfection or transformation with the expression vector. According to some specific embodiments of the present invention, the recombinant cell can efficiently express the recombinant antibody under suitable conditions, and the recombinant cell can be effectively used for specific treatment or prevention of tumors, especially tumors expressing B7H6.
[0084] In addition, the term "suitable conditions" as used herein refers to conditions suitable for the expression of the recombinant antibody described herein. As can be easily understood by those skilled in the art, suitable conditions for the expression of the recombinant antibody include, but are not limited to, a suitable transformation or transfection method, suitable transformation or transfection conditions, healthy host cell state, suitable host cell density, suitable cell culture environment, and suitable cell culture time. The "suitable conditions" are not particularly limited, and those skilled in the art will optimize the optimal conditions for the expression of the recombinant antibody according to the specific environment of the laboratory.
[0085] In the sixth aspect of the present invention, the present invention proposes a composition, comprising the recombinant antibody according to the first or second aspect, the nucleic acid molecule according to the third aspect, the expression vector according to the fourth aspect, or the recombinant cell according to the fifth aspect. As mentioned above, the recombinant antibody according to the embodiment of the present invention can effectively bind to CD3 or B7H6 protein molecule, and specifically recognize tumor cells with high expression of B7H6, and can induce T cells to selectively localize in the tumor area instead of circulating in the periphery, avoiding systemic activation, and the recombinant antibody and a corresponding series of compositions of substances, such as food compositions or drug compositions, also have a significant effect of treating or preventing tumors expressing B7H6, and its safety is higher and side effects are smaller.
[0086] In the eighth aspect of the present invention, the present invention proposes a drug, comprising the recombinant antibody according to the first or second aspect, the nucleic acid molecule according to the third aspect, the expression vector according to the fourth aspect, the recombinant cell according to the fifth aspect or the composition according to the sixth aspect, said drug being used for the treatment and prevention of cancer. As mentioned above, the recombinant antibody according to the embodiment of the present invention can effectively bind to CD3 or B7H6 protein molecule, and further specifically recognize tumor cells with high expression of B7H6, so as to induce T cells to selectively localize in the tumor site instead of circulating in the periphery, and avoid systemic activation, and said drug comprising the recombinant antibody-based substance also has a significant effect of treating or preventing tumors expressing B7H6, and its safety is higher and side effects are smaller.
[0087] According to some specific embodiments of the present invention, the cancer comprises at least one of colon cancer, non-small cell lung cancer, breast cancer and liver cancer.
[0088] The medicament according to some specific embodiments of the present invention comprises a pharma- ceutically acceptable vector and an effective amount of the antibody active ingredient.
[0089] As used herein, the term "effective amount" or "effective dosage" refers to an amount that produces a function or activity in humans and / or animals and is acceptable to humans and / or animals.
[0090] As used herein, a "pharmaceutically acceptable" component is a substance that may be administered to humans and / or mammals without undue adverse side effects (e.g., toxicity, irritation, and allergic reactions), i.e., with a reasonable benefit / risk ratio. The term "pharmaceutically acceptable vector" refers to a vector used to administer a therapeutic agent, including various excipients and diluents.
[0091] The drug of the present invention comprises a safe and effective amount of the active ingredient of the present invention and a pharma- ceutically acceptable vector. Such vectors include (but are not limited to) saline, buffer, glucose, water, glycerin, ethanol, and combinations thereof. The usual drug formulation should match the mode of administration, and the dosage form of the drug of the present invention is injection, oral preparation (tablet, capsule, oral liquid), transdermal agent, sustained release agent. For example, it is prepared by a usual method using an aqueous solution containing physiological saline, glucose, and other auxiliary agents. The drug is preferably prepared under aseptic conditions.
[0092] The effective amount of the active ingredient according to the present invention varies depending on the mode of administration and the severity of the disease to be treated. The selection of a preferred effective amount can be determined by those skilled in the art based on various factors (e.g., clinical trials). Such factors include, but are not limited to, the pharmacokinetic parameters of the active ingredient, such as bioavailability, metabolism, and half-life, the severity of the disease the patient is being treated for, the patient's body weight, the patient's immune status, and the route of administration. For example, depending on the urgent needs of the treatment situation, multiple separate doses can be administered per day, or the dosage can be reduced proportionately.
[0093] Pharmaceutically acceptable vectors according to the present invention include, but are not limited to, water, saline, liposomes, lipids, proteins, protein-antibody complexes, peptide-based substances, cellulose, nanogels, or combinations thereof. The choice of vector should match the mode of administration, which are well known to those skilled in the art.
[0094] use In the seventh aspect of the present invention, the present invention proposes the use of the recombinant antibody according to the first or second aspect, the nucleic acid molecule according to the third aspect, the expression vector according to the fourth aspect, the recombinant cell according to the fifth aspect, or the composition according to the sixth aspect in the preparation of a drug for treating or preventing tumors. As mentioned above, the recombinant antibody provided in some specific embodiments of the present invention can effectively bind to CD3 and B7H6 protein, and can specifically recognize highly specific tumor cells expressing B7H6, and the drug prepared using the recombinant antibody and a series of corresponding substances also has a significant effect of treating or preventing tumors expressing B7H6, with higher safety and less side effects.
[0095] According to some specific embodiments of the present invention, the above use may further include at least one of the following additional technical features:
[0096] According to some specific embodiments of the present invention, the tumor comprises at least one of colon cancer, non-small cell lung cancer, breast cancer and liver cancer.
[0097] kit In a ninth aspect of the present invention, the present invention provides a kit, comprising a recombinant antibody according to the first or second aspect. The recombinant antibody provided in some specific embodiments of the present invention can bind to B7H6 protein, and thus the kit comprising the recombinant antibody can be used to effectively diagnose or detect tumors that highly express the B7H6 protein.
[0098] According to some specific embodiments of the present invention, the kit is used for diagnosing or detecting at least one of rectal cancer, non-small cell lung cancer, breast cancer and liver cancer. The recombinant antibody provided in some specific embodiments of the present invention can effectively bind to CD3 and B7H6 protein molecules, and can specifically recognize highly specific tumor cells expressing B7H6, so that the recombinant antibody can be used to manufacture a kit for diagnosing or detecting at least one of rectal cancer, non-small cell lung cancer, breast cancer and liver cancer, and the kit can be used in scientific research, such as qualitative or quantitative detection of CD3 and / or B7H6 protein molecules in biological samples.
[0099] Uses and methods for treating diseases In the tenth aspect of the present invention, the present invention proposes the use of the above recombinant antibody, nucleic acid molecule, expression vector, recombinant cell, composition or drug in treating or preventing cancer. As described above, when the recombinant antibody can specifically recognize the above CD3 and / or B7H6 protein, the CD3 antibody affinity is in an appropriate range, and the tumor target-related antibody has a high affinity, the bispecific antibody can selectively localize T cells to the tumor local instead of the peripheral circulation, effectively treating or preventing cancer while avoiding systemic activation. Therefore, the recombinant antibody according to the embodiment of the present invention, the composition of the recombinant antibody, drug and a series of substances that can be expressed to obtain the recombinant antibody under appropriate conditions, such as the above nucleic acid molecule, expression vector, recombinant cell, etc., can all be used to treat or prevent cancer.
[0100] According to some specific embodiments of the present invention, the cancer comprises at least one of colon cancer, non-small cell lung cancer, breast cancer and liver cancer.
[0101] In the eleventh aspect of the present invention, the present invention provides a method for treating or preventing cancer. According to some specific embodiments of the present invention, the method includes administering to a subject at least one of the following: 1) the above recombinant antibody, 2) the above nucleic acid molecule, 3) the above expression vector, 4) the above recombinant cell, or 5) the above composition. As described above, when the recombinant antibody can specifically recognize the above CD3 and / or B7H6 protein, the CD3 antibody affinity is in an appropriate range, and the tumor target-related antibody has high affinity, the bispecific antibody can selectively localize T cells to the tumor locale instead of the peripheral circulation, effectively treating and preventing cancer while avoiding systemic activation, and thus the method according to the embodiments of the present invention can effectively treat and prevent cancer and avoid systemic activation of T cells.
[0102] According to some specific embodiments of the present invention, the cancer comprises at least one of colon cancer, non-small cell lung cancer, breast cancer and liver cancer.
[0103] The following examples are specifically described. If no specific techniques or conditions are shown in the examples, they are carried out according to the techniques or conditions described in the literature in the field or according to the product specifications. If no manufacturer is shown for the reagents or equipment used, they are conventional products that can be purchased commercially.
[0104] Example 1. Design and construction of CD3×B7H6 bispecific antibody molecules
[0105] In this example, by screening multiple configurations, the inventors have determined a bispecific antibody configured with scFv-Fc, which is named CD3xB7H6, which comprises two monovalent units, one of which is in the ScFv-Fc format of anti-CD3 and the other is in the ScFv-Fc format of anti-B7H6, a linking peptide connects the light chain variable region and the heavy chain variable region of the CD3 antibody, and a linking peptide similar to the above connects the light chain variable region and the heavy chain variable region of the B7H6 antibody, the linking peptide having the amino acid sequence shown in SEQ ID NO:46, the CD3 antibody having the light chain variable region shown in SEQ ID NO:13 and the heavy chain variable region shown in SEQ ID NO:14, the B7H6 antibody having the light chain variable region shown in SEQ ID NO:15-20 and the heavy chain variable region shown in SEQ ID NO:21-26. Here, the inventors screened different combinations of B7H6 antibody variable domains and CD3 antibody variable domains, constructed 18 CD3×B7H6 recombinant antibody molecules, and modified Fc of the monovalent unit by amino acid mutation, in which the amino acids in the anti-CD3 Fc domain are changed to cysteine (S384C) at position 384 and to tryptophan (T396W) at position 396, and the amino acids in the anti-B7H6 Fc domain are changed to cysteine (Y380C) at position 380, to serine (T397S) at position 397, to alanine (L399A) at position 399, and to valine (Y408V) at position 408, respectively, which makes it difficult to form homodimers, but easy to form heterodimers, and the heterodimer is a bispecific antibody CD3×B7H6, the specific structure of which is shown in FIG. 1. The 18 CD3×B7H6 recombinant antibody molecules are represented by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4. It has a CD3 single chain antibody shown in ID NO:27, a B7H6 single chain antibody shown in SEQ ID NO:28-45, a first antibody Fc region shown in SEQ ID NO:47, and a second antibody Fc region shown in SEQ ID NO:48, both of which are linked in a knob-into-hole structure after the above mutations.
[0106] Using common molecular biology techniques, the nucleic acid sequences encoding the polypeptide chains of CD3 and B7H6(1-18) monovalent units were cloned into expression vector pTT5 (Youbao Bio, Catalog No. VT2202), respectively, with specific nucleotide sequences at least one of SEQ ID NO:69 and SEQ ID NO:70-87. At the same time, in order to efficiently express in CHO cells and secrete into the medium, the lead peptide of mouse-derived antibody kappa chain was selected as a secretory signal peptide and inserted into the expression vector, with the signal peptide located at the N-terminus of the antibody variable region, and its amino acid sequence is METDTLLLWVLLLWVPGSTG (SEQ ID NO:68), and the nucleotide sequence encoding the signal peptide is shown in SEQ ID NO:88.
[0107] ATGGAGACCGACACCCTGCTGCTGTGGGTGCTGCTGCTGTGGGTGCCCGGCTCCACCGGC (SEQ ID NO:88).
[0108] CD3 single chain antibody MDIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIKGGGGSGGGGSGGGGSE VQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSS(SEQ ID NO:27).
[0109] B7H6-1 single chain antibody DIVLTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWMGDINPNNGGTLYNQKFRGRVTMTVDTSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSS(SEQ ID NO:28).
[0110] B7H6-2 single-chain antibody DIVLTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWIGDINPNNGGTLYNQKFRGRVTLTVDTSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSS(SEQ ID NO:29).
[0111] B7H6-3 single-chain antibody DIVLTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWIGDINPNNGGTLYNQKFRGRVTLTVDKSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSS(SEQ ID NO:30).
[0112] B7H6-4 single-chain antibody DIVLTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGKGLEWIGDINPNNGGTLYNQKFRGRVTLTVDKSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSS(SEQ ID NO:31).
[0113] B7H6-5 single-chain antibody DIVLTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGIPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWMGDINPNNGGTLYNQKFRGRVTMTVDTSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSS(SEQ ID NO:32).
[0114] B7H6-6 single-chain antibody DIVLTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGIPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWIGDINPNNGGTLYNQKFRGRVTLTVDTSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSS(SEQ ID NO:33).
[0115] B7H6-7 single-chain antibody DIVLTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGIPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWIGDINPNNGGTLYNQKFRGRVTLTVDKSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSS(SEQ ID NO:34).
[0116] B7H6-8 single-chain antibody DIVLTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGIPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGKGLEWIGDINPNNGGTLYNQKFRGRVTLTVDKSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSS(SEQ ID NO:35).
[0117] B7H6-9 single-chain antibody DIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSYMNWYLQKPGQPPQLLIYAASTLHSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWMGDINPNNGGTLYNQKFRGRVTMTVDTSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSS(SEQ ID NO:36).
[0118] B7H6-10 single-chain antibody DIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSYMNWYLQKPGQPPQLLIYAASTLHSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWIGDINPNNGGTLYNQKFRGRVTLTVDTSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSS(SEQ ID NO:37).
[0119] B7H6-11 single-chain antibody DIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSYMNWYLQKPGQPPQLLIYAASTLHSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWIGDINPNNGGTLYNQKFRGRVTLTVDKSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSS(SEQ ID NO:38).
[0120] B7H6-12 single-chain antibody DIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSYMNWYLQKPGQPPQLLIYAASTLHSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGKGLEWIGDINPNNGGTLYNQKFRGRVTLTVDKSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSS(SEQ ID NO:39).
[0121] B7H-13 single-chain antibody DIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSYMNWYLQKPGQPPQLLIYAASTLHSGIPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWMGDINPNNGGTLYNQKFRGRVTMTVDTSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSS(SEQ ID NO:40).
[0122] B7H6-14 single-chain antibody DIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSYMNWYLQKPGQPPQLLIYAASTLHSGIPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWIGDINPNNGGTLYNQKFRGRVTLTVDTSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSS(SEQ ID NO:41).
[0123] B7H6-15 single-chain antibody DIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSYMNWYLQKPGQPPQLLIYAASTLHSGIPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWIGDINPNNGGTLYNQKFRGRVTLTVDKSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSS(SEQ ID NO:42).
[0124] B7H6-16 single-chain antibody DIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSYMNWYLQKPGQPPQLLIYAASTLHSGIPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGG SEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGKGLEWIGDINPNNGGTLYNQKFRGRVTLTVDKSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSS(SEQ ID NO:43).
[0125] B7H6-17 single chain antibody DIVLTQSPVSLAVPLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGIPVRFSGSGSGTDFTLNIHPVEEEDAASYYCQQSKEDPRTFGGGTKLEIKGGGGSGGGGSGGGG SEVLLQQSGPEVVKPGASVKITCKASGYTFTDYNMDWVKQSHGKSLEWIGDINPNNAGTLYNQKFRGRVTLIVDKSSSTAYMELRSLTSDDTAVYYCARSEVFYGNYADYWGQGTTLTVSS(SEQ ID NO:44).
[0126] B7H6-18 single chain antibody DIVLTQSPVSLAVPLGQRATISCKASQSVDYDADSYMNWYQQKPGQPPKLLIYAASTLHSGIPVRFSGSGSGTDFTLNIHPVEEEDAASYYCQQSKEDPRTFGGGTKLEIKGGGGSGGGGSGGGG SEVLLQQSGPEVVKPGASVKITCKASGYTFTDYNMDWVKQSHGKSLEWIGDINPNNGGTLYNQKFRGRVTLIVDKSSSTAYMELRSLTSDDTAVYYCARSEVFYGNYADYWGQGTTLTVSS(SEQ ID NO:45).
[0127] Amino acid sequence of the first Fc region EPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALAPIE KTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:47).
[0128] Amino acid sequence of the second Fc region EPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALAPIE KTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:48).
[0129] Example 2 Expression and purification of CD3×B7H6 bispecific antibodies
[0130] 2.1 Expression of CD3×B7H6 bispecific antibody molecules The bispecific molecules that bind to CD3 and B7H6 were prepared by transfecting ExpiCHO-S cells (Gibco, Cat. No. A29127) with pTT5 vector carrying CD3×B7H6 chain-encoding genes, where each of the 18 CD3×B7H6 chain-encoding genes has an anti-CD3 ScFv-Fc shown in SEQ ID NO:49 and an anti-B7H6 ScFv-Fc shown in SEQ ID NO:50-67. The specific experimental procedure is as follows: the day before transfection, ExpiCHO-S cells were cultured at a cell density of (3-4)×10 6The cells were adjusted to a concentration of 7 × 10 6 -1×10 7 Once cells have grown to 6 × 10 / mL and viability is greater than 95%, prepare for transfection by dissolving the cells in fresh, prewarmed ExpiCHO medium (Gibco, catalog no. A2910002). 6 The plasmids containing the CD3 and B7H6 polypeptide chains were diluted to 1000 / mL and transfected into ExpiCHO-S cells at a mass ratio of 1:1 using ExpiFectamine CHO transfection reagent (Gibco, catalog number A29129), and cultured at 37°C, 8% CO2, and 120 rpm with rocking. 18-22 h after transfection, ExpiFectamine CHO Enhancer and ExpiCHO Feed were mixed uniformly and immediately added to the transfected cells, mixed uniformly, and cultured at 32°C, 5% CO2, and 120 rpm with rocking. Five days after transfection, 8 mL of ExpiCHO Feed was added again to the cells, mixed uniformly, and cultured. The changes in cell number and cell viability were observed every day, and either waited until cell viability dropped to 80% or less, or after 10-14 days of culture, the cells were centrifuged to obtain the cells, and the supernatant was purified or frozen at -80°C for spare use.
[0131] 2.2 Purification of CD3×B7H6 bispecific antibody molecules 2.1 The supernatant obtained in the experiment was filtered through a 0.22 μm filter membrane, and the antibody with the Fc structural domain was captured from the expression supernatant using a Mabselect prism A affinity chromatography column (GE Company, Catalog No. 17549854). After equilibrating the chromatography column with phosphate buffer at pH 7.2, the supernatant was passed through the affinity chromatography column and eluted with elution buffer (100 mM citric acid, pH 2.7), and finally, it was concentrated and replaced with PBS buffer, and the purified antibody was identified by SDS-PAGE to have a purity of more than 95%.
[0132] CD3 ScFv-Fc amino acid sequence MDIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIKGGGGSGGGGSGG GGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTL VTVSSEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:49).
[0133] B7H6-1ScFv-Fc amino acid sequence DIVLTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWMGDINPNNGGTLYNQKFRGRVTMTVDTSISTAYMELSRLRSDDTAVYCARSEVGYNYADYWGQGTT VTVSSEPKSCDKTHTCPPCPAPEAAGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPGK(SEQ ID NO:50)。
[0134] B7H6-2 ScFv-Fc amino acid sequence DIVLTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWIGDINPNNGGTLYNQKFRGRVTLTVDTSISTAYMELSRLRSDDTAVYCARSEVGYNYADYWGQGTT VTVSSEPKSCDKTHTCPPCPAPEAAGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPGK(SEQ ID NO:51)。
[0135] B7H6-3 ScFv-Fc amino acid sequence DIVLTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWIGDINPNNGGTLYNQKFRGRVTLTVDKSISTAYMELSRLRSDDTAVYCARSEVGYNYADYWGQGTT VTVSSEPKSCDKTHTCPPCPAPEAAGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPGK(SEQ ID NO:52)。
[0136] B7H6-4 ScFv-Fc amino acid sequence DIVLTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGKGLEWIGDINPNNGGTLYNQKFRGRVTLTVDKSISTAYMELSRLRSDDTAVYCARSEVGYNYADYWGQGTT VTVSSEPKSCDKTHTCPPCPAPEAAGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPGK(SEQ ID NO:53)。
[0137] B7H6-5 ScFv-Fc amino acid sequence DIVLTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGIPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWMGDINPNNGGTLYNQKFRGRVTMTVDTSISTAYMELSRLRSDDTAVYCARSEVGYNYADYWGQGTT VTVSSEPKSCDKTHTCPPCPAPEAAGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPGK(SEQ ID NO:54)。
[0138] B7H6-6 ScFv-Fc amino acid sequence DIVLTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGIPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWIGDINPNNGGTLYNQKFRGRVTLTVDTSISTAYMELSRLRSDDTAVYCARSEVGYNYADYWGQGTT VTVSSEPKSCDKTHTCPPCPAPEAAGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPGK(SEQ ID NO:55)。
[0139] B7H6-7 ScFv-Fc amino acid sequence DIVLTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGIPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGSGGGSEGGGSESEVQLVQSGAEVKKPGASVKVSCKASGYTFDTDYNMDWVRQAPGQGLEWIGDINPNNGGTLYNQKFRGRVTLTVDKSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSSEPKSCDKTHTCPPCPPAPEAAGGPSVFLFPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:56).
[0140] B7H6-8 ScFv-Fc amino acid sequence DIVLTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGIPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGSGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFDTYNMDWVRQAPGKGLEWIGDINPNNGGTLYNQKFRGRVTLTVDKSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSSEPKSCDKTHTCPPCPPAPEAAGGPSVFLFPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:57).
[0141] B7H6-9 ScFv-Fc amino acid sequence DIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSYMNWYLQKPGQPPQLLIYAASTLHSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWMGDINPNNGGTLYNQKFRGRVTMTVDTSISTAYMELSRLRSDDTAVYCARSEVGYNYADYWGQGTT VTVSSEPKSCDKTHTCPPCPAPEAAGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPGK(SEQ ID NO:58)。
[0142] B7H6-10 ScFv-Fc amino acid sequence DIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSYMNWYLQKPGQPPQLLIYAASTLHSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWIGDINPNNGGTLYNQKFRGRVTLTVDTSISTAYMELSRLRSDDTAVYCARSEVGYNYADYWGQGTT VTVSSEPKSCDKTHTCPPCPAPEAAGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPGK(SEQ ID NO:59)。
[0143] B7H6-11 ScFv-Fc amino acid sequence DIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSYMNWYLQKPGQPPQLLIYAASTLHSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWIGDINPNNGGTLYNQKFRGRVTLTVDKSISTAYMELSRLRSDDTAVYCARSEVGYNYADYWGQGTT VTVSSEPKSCDKTHTCPPCPAPEAAGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPGK(SEQ ID NO:60)。
[0144] B7H6-12 ScFv-Fc amino acid sequence DIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSYMNWYLQKPGQPPQLLIYAASTLHSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGKGLEWIGDINPNNGGTLYNQKFRGRVTLTVDKSISTAYMELSRLRSDDTAVYCARSEVGYNYADYWGQGTT VTVSSEPKSCDKTHTCPPCPAPEAAGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPGK(SEQ ID NO:61)。
[0145] B7H6-13 ScFv-Fc amino acid sequence DIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSYMNWYLQKPGQPPQLLIYAASTLHSGIPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWMGDINPNNGGTLYNQKFRGRVTMTVDTSISTAYMELSRLRSDDTAVYCARSEVGYNYADYWGQGTT VTVSSEPKSCDKTHTCPPCPAPEAAGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPGK(SEQ ID NO:62)。
[0146] B7H6-14 ScFv-Fc amino acid sequence DIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSYMNWYLQKPGQPPQLLIYAASTLHSGIPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGGSGGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWIGDINPNNGGTLYNQKFRGRVTLTVDTSISTAYMELSRLRSDDTAVYCARSEVGYNYADYWGQGTT VTVSSEPKSCDKTHTCPPCPAPEAAGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPGK(SEQ ID NO:63)。
[0147] B7H6-15 ScFv-Fc amino acid sequence DIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSYMNWYLQKPGQPPQLLIYAASTLHSGIPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGSGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFDTDYNMDWVRQAPGQGLEWIGDINPNNGGTLYNQKFRGRVTLTVDKSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSSEPKSCDKTHTCPPCPPAPEAAGGPSVFLFPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:64).
[0148] B7H6-16 ScFv-Fc amino acid sequence DIVLTQTPLSLVTGQPASISCKASQSVDYDGDSYMNWYLQKPGQPPQLLIYAASTLHSGIPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSKEDPRTFGQGTKLEIKGGGGSGGGSGGGSEVQLVQSGAEVKKPGASVKVSCKASGYTFDTYNMDWVRQAPGKGLEWIGDINPNNGGTLYNQKFRGRVTLTVDKSISTAYMELSRLRSDDTAVYYCARSEVFYGNYADYWGQGTTVTVSSEPKSCDKTHTCPPCPPAPEAAGGPSVFLFPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:65).
[0149] B7H6-17 ScFv-Fc amino acid sequence DIVLTQSPVSLAVPLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASTLHSGIPVRFSGSGSGTDFTLNIHPVEEDAASYCQQSKEDPRTFGGGTKLEIKGGGGSGGGGSGGGSEVLLQQSGPEVVKPGASVKITCKASGYTFTDYNMDWVKQSHGKSLEWIGDINPNNAGTLYNQKFRVTLIVDKSSSTAYMELRSLTSDTAVYCARSEVHYGNYADYWGQGTT LTVSSEPKSCDKTHTCPPCPAPEAAGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLPG(SEQ ID NO:66)。
[0150] B7H6-18 ScFv-Fc amino acid sequence DIVLTQSPVSLAVPLGQRATISCKASQSVDYDADSYMNWYQQKPGQPPKLLIYAASTLHSGIPVRFSGSGSGTDFTLNIHPVEEEDAASYYCQQSKEDPRTFGGGTKLEIKGGGGGSGGGG SGGGGSEVLLQQSGPEVVKPGASVKITCKASGYTFTDYNMDWVKQSHGKSLEWIGDINPNNGGTLYNQKFRGRVTLIVDKSSSTAYMELRSLTSDDTAVYYCARSEVFYGNYADYWGQGTT LTVSSEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:67).
[0151] Example 3 Detection of binding activity of CD3×B7H6 bispecific antibody to antigen (ELISA)
[0152] In this example, the binding activity of the CD3×B7H6 bispecific antibody to a single antigen (B7H6 antigen or CD3 antigen) and the binding activity of the CD3×B7H6 bispecific antibody to simultaneous binding of two antigens (B7H6 antigen, CD3 antigen) were detected. The specific experimental procedures are as follows:
[0153] 3.1 Measurement of binding activity of CD3×B7H6 bispecific antibody to single antigens Human B7H6 (ACRO biosystems, Cat. No. B76-H52H8) and human CD3 antigen (ACRO biosystems, Cat. No. CDD-H52W1) were each diluted to 2 μg / mL in coating buffer (35 mM NaHCO3, 15 mM Na2CO3, pH 9.6) and added to the enzyme-binding plate at 100 μL per well and incubated overnight at 4°C. The plate was then washed three times with PBST (0.05% Tween 20-PBS, pH 7.2). 300 μL of blocking buffer (1% BSA, 0.05% Tween 20-PBS, pH 7.2) was added to the plate and incubated at room temperature for 2 h. The plate was further washed three times with PBST. The corresponding bispecific antibody was added per well and incubated at room temperature for 1 h. The plate was then washed three times with PBST. Add 100μL of HRP-rabbit anti-human IgG secondary antibody (boster, catalogue no. BA1070) diluted in blocking buffer per well and incubate at room temperature for 1 hour. Wash 3 times with PBST, add TMB per well and incubate at room temperature for 2-5 minutes in the dark. Stop the reaction with 2M sulfuric acid in each well and finally read the OD450 value with a microplate reader.
[0154] Specific experimental results are shown in Figure 2A, which shows the binding situation between CD3×B7H6 bispecific antibody molecules composed of different B7H6 sequences and CD3 sequences and B7H6 antigen, and all of these bispecific antibody molecules can bind to B7H6 antigen, whereby the binding activity of CD3×B7H6-14 is the strongest, and therefore subsequent experiments will mainly focus on CD3×B7H6-14, and Figure 2B shows that the CD3×B7H6-14 bispecific antibody molecule can bind to CD3 antigen.
[0155] 3.2 Measurement of binding activity of CD3×B7H6 bispecific antibody and dual antigens Human B7H6 (ACRO biosystems, Cat. No. B76-H82Wb) was diluted to 2 μg / mL in coating buffer (35 mM NaHCO3, 15 mM Na2CO3, pH 9.6) and 100 μL per well was added to the enzyme-binding plate and incubated overnight at 4 °C. The plate was then washed three times with PBST (0.05% Tween 20-PBS, pH 7.2). 300 μL of blocking buffer (1% BSA, 0.05% Tween 20-PBS, pH 7.2) was added to the plate and incubated for 2 h at room temperature. The plate was washed three times with PBST. The corresponding bispecific antibody was added per well and incubated for 1 h at room temperature. The plate was washed three times with PBST. 100 μL of human CD3 antigen (ACRO biosystems, Cat. No. CDD-H52W1) diluted in blocking buffer was added per well and incubated for 1 h at room temperature. Washed 3 times with PBST. 100μL of HRP-anti-His tagged secondary antibody (Genscript, Cat. No. A00612) diluted with blocking buffer was added per well and incubated at room temperature for 1 hour. Washed 3 times with PBST, TMB was added per well, and incubated at room temperature for 2-5 minutes in the dark. Each well was stopped with 2M sulfuric acid, and finally the OD450 reading was done with a microplate reader. The specific results are shown in Figure 2C. The results show that with the increase in the concentration of the CD3×B7H6-14 bispecific antibody molecule, its OD450 reading gradually increases, indicating that the bispecific antibody molecule can bind to human CD3 and B7H6 simultaneously.
[0156] Example 4 In vitro killing detection of bispecific antibody molecules
[0157] 4.1 Isolation of human peripheral blood mononuclear cells (PBMCs) Anticoagulated human peripheral blood was added to the same volume of sterile PBS, and a 50mL sterile centrifuge tube was taken, and 25mL of diluted peripheral blood was gently added to 15mL of lymph separation solution (GE healthcare, catalog number 17144003), keeping the interface from shaking clearly throughout the process, and centrifuged at 21°C, 400g for 30min, 1 acceleration and 0 deceleration of the centrifuge. After centrifugation, the inside of the tube was divided into three layers, the middle layer was the lymphocyte layer, and the middle white film layer was aspirated into a new 50mL centrifuge tube, filled to 50mL with PBS after aspirating, and centrifuged at 500g for 10min. The supernatant was discarded, 1mL of PBS was added, blown gently and evenly, filled to 40mL with PBS, and centrifuged at 250g for 10min.
[0158] After centrifugation, the supernatant is discarded and the cells are resuspended in 1 mL of MACS buffer (0.5% BSA, 2.5 mM EDTA-PBS) prior to dilution and counting.
[0159] 4.2 Isolation of purified T cells Human T cells were isolated from peripheral blood using magnetic bead sorting (Miltenyi, Catalog No. 130096535). PBMCs were collected and the supernatant was discarded completely. 7 The cells were resuspended by adding 40 μL of MACS buffer for each cell, and then 10 μL of T Cell Biotin-Antibody Cocktail was added, mixed uniformly, and incubated at 4°C for 10 min. 7 Add 30 μL of MACS buffer and 20 μL of T Cell MicroBead Cocktail for each cell, mix evenly, and incubate at 4°C for 15 min. Place the LS separation column in the magnetic field, wet the separation column with 3 mL of MACS buffer, add the cell suspension to the separation column, wash the centrifuge tube with 1 mL of MACS buffer, add the separation column, and collect the effluent. Wash the separation column with 3 mL of MACS buffer and collect the effluent. After mixing evenly, count the cells. Centrifuge the cell suspension at 300 g for 10 min at 4°C and resuspend in medium.
[0160] 4.3 Detection of in vitro killing of adherent cultured tumor cells Adherent tumor cells were digested and counted to determine a cell density of 2 × 10 5 Adjust to 100 μL / mL. Select RTCA instrument (Agilent), instrument type DP, select experiment mode, and enter cell and drug information. Enter schedule setting experiment step, add 50 μL of fresh medium (89% RPMI 1640 medium + 10% fetal bovine serum + 1% penicillin) to the plate, then place in the instrument to close, click first step to start. After Done completion, remove the plate, add 100 μL of cell suspension, leave at room temperature for 15-30 min to prevent edge effect, place in the instrument, click start. After growth to log phase, pause and add 50 μL of purified T cells (1 × 10 6 1 / mL), bispecific antibodies were added at gradient concentrations, clicked start, and analyzed after a set time.
[0161] Specific experimental results, as shown in the figures, with increasing concentrations of CD3×B7H6-14 bispecific antibody, the killing efficiency of T cells against HCT-15 cells (Figure 3A), LoVo cells (Figure 3B), Hep G2 cells (Figure 3C), and SK-BR-3 cells (Figure 3D) gradually increased, indicating that CD3×B7H6-14 can promote the killing of B7H6+ tumor cells by T cells.
[0162] Example 5: Detection of in vitro death of floating cells by luciferase reaction method Luciferase-overexpressing tumor cells were harvested and then cultured at a cell density of 2 × 10 5 The T cells were isolated, collected, and purified as described in Examples 4.1 and 4.2 to a cell density of 5 × 10 550μL of tumor cells and purified T cells were each placed in a 96-well flat plate, and the bispecific antibodies were added at gradient concentrations and mixed uniformly. After 4 hours of incubation at 37℃ and 5% CO2, 100μL (15mg / mL) of fluorescein potassium salt solution (Goldbio, Catalog No. LUCK-1G) was added per well, mixed quickly and uniformly, and the chemiluminescence value was detected by a microplate reader.
[0163] Specific experimental results, as shown in the figures, showed that with increasing concentrations of CD3×B7H6-14 bispecific antibody, the chemiluminescence values of Ho8910 and K562 gradually decreased, and fewer surviving tumor cells were detected, indicating that CD3×B7H6-14 could significantly promote the killing of Ho8910 cells (Figure 4A) and K562 cells (Figure 4B) by T cells.
[0164] Example 6 Detecting the proliferation status of T cells in the presence of B7H6-positive tumor cells In order to measure the proliferation of T cells, a 2*2 two-factor experiment was set up in this example, including a T cell + PBS group, a T cell + CD3 × B7H6-14 group, a HCT-15 + T cell + PBS group, and a HCT-15 + T cell + CD3 × B7H6-14 group. As described in Examples 4.1 and 4.2, T cells were separated and purified, and the purified T cells were marked with 5 μM Cell Trace CFSE (Invitrogen, Catalog No. C34554). Then, the marked T cells were mixed with human colon cancer cells (HCT-15 cells) at a target ratio of 2:1, into which PBS or bispecific antibodies were added, and the cells were collected after 3 days, and the proliferation status of T cells was detected by flow cytometry.
[0165] Specific experimental results, as shown in the figure, show that the CD3×B7H6-14 bispecific antibody can significantly promote T cell proliferation in the presence of HCT-15 (FIG. 5A), and with increasing concentration of the bispecific antibody CD3×B7H6-14, the promoting effect on T cell proliferation becomes significant (FIG. 5B).
[0166] Example 7 Detecting T cell activation and degranulation levels in the presence of B7H6-positive tumor cells As described in Examples 4.1 and 4.2, T cells were separated and purified, and in the experiment, a total of two groups were set up, the control group was the T cell group, and the experimental group was the T cell and HCT-15 target cells were added into a 96-well plate with a target ratio of 1:1, and CD3 × B7H6 bispecific antibody was added at gradient concentrations and mixed uniformly. After incubation at 37 ° C for 24 hours, the cells were collected by centrifugation, resuspended in PBS, and mouse serum was added to block at room temperature for 15 minutes, and flow cytometry antibodies to detect surface molecules were added, incubated at 4 ° C for 30 minutes in the dark, washed with PBS, and then fixed transmembrane solution (invitrogen, catalog number 00512343) was added and fixed at room temperature for more than half an hour. Further, transmembrane buffer (invitrogen, catalog number 00833356) was added and washed, and mouse serum was added to block at room temperature for 15 minutes, and then the corresponding intracellular molecule mark antibody was added, incubated at room temperature for 30 minutes in the dark, and then PBS was added and washed twice, and then detected by flow cytometry.
[0167] Specific experimental results, as shown in Figures 6A and 6B, in the presence of B7H6+ cells (+HCT-15), with increasing concentrations of CD3 × B7H6-14 bispecific antibody, the proportion of CD4+ T cells and CD8+ T cells expressing CD69 molecules on their surface (Figure 6A) and expressing CD107a molecules intracellularly (Figure 6B) gradually increased; in the absence of B7H6+ tumor cells (-HCT-15), the activation and degranulation abilities of T cells after incubation with the bispecific antibody were very limited, indicating that the bispecific antibody can specifically target T cells and B7H6+ tumor cells and promote the activation and degranulation of T cells.
[0168] Example 8 Detecting secreted cellular factors of T cells in the presence of B7H6-positive tumor cells T cells were isolated and purified as described in Examples 4.1 and 4.2. The control group contained only T cells, and the experimental group contained T cells and HCT-15 cells, with 5 × 10 5 T cells, 5 x 10 55 x 10 T cells and 5 x 10 5 HCT-15 cells were added to each well of a 24-well plate in a total volume of 500 μL, and CD3×B7H6 bispecific antibody (0, 10 0 , 10 1 , 10 2 , 10 3 ) was added at gradient concentrations and mixed uniformly. After incubation at 37°C for 24 hours, the mixture was centrifuged and the supernatant was collected. The concentrations of various cell factors in the supernatant were detected using a CBA human Th1 / Th2 / Th17 cell factor detection kit (BD, catalog number 560484), and finally detected by flow cytometry.
[0169] Specific experimental results, as shown in Figures 7A-D, show the concentration of cells co-incubating with IFN-γ, IL-2, IL-10 and IL-17A cellular factors in the supernatant. In the presence of HCT-15 tumor cells, with the increase in the concentration of CD3 x B7H6-14 antibody, the level of T cells secreting these four cellular factors also gradually increased, indicating that the bispecific antibody can promote the activation of T cells to secrete cellular factors.
[0170] Example 9 Study on the effect of in vivo xenotransplantation To detect the in vivo antitumor activity of CD3×B7H6 bispecific antibody molecule against HCT-15 tumor cells, the experiment was conducted in this example with a total of three groups, including a buffer group, a human immunoglobulin (IGg) group, and a CD3×B7H6-14 bispecific antibody molecule group. As described in Examples 4.1 and 4.2, T cells were separated and purified, and then T cells were expanded for 7 days using a T cell expansion kit (Gibco, Cat. No. 11131D). HCT-15 colon cancer cells (1×10 6 ) and expanded T cells (2 × 10 6), and then (sc) was injected subcutaneously into male NOD-Prkdcscid Il2rgem1 / Smoc mice. Every 2 days after inoculation, the mice were intravenously injected with CD3xB7H6 bispecific antibody (1 mg / kg, dissolved in PBS), IgG control antibody (Sigma, Cat. No. I4506), or buffer (control solvent) for a total of 3 injections. Tumor length and width were detected by external caliper measurements, and tumor volume was calculated using standard formulas.
[0171] Figure 8 shows the in vivo antitumor activity of the CD3 x B7H6-14 bispecific antibody molecule against HCT-15 cells. Treatment with the CD3 x B7H6-14 bispecific antibody can significantly promote the regression of HCT-15 tumors, while the use of control IgG or control solvent fails to achieve therapeutic effect, indicating that the CD3 x B7H6 bispecific antibody has significant in vivo antitumor activity.
[0172] In the present specification, the reference words such as "one embodiment", "some embodiments", "examples", "specific examples", or "some examples" mean that the specific features, structures, materials, or characteristics described in the embodiment or example are included in at least one embodiment or example of the present invention. In the present specification, the above-mentioned terms and exemplary descriptions do not necessarily refer to the same embodiment or example. In addition, the specific features, structures, materials, or characteristics described can be combined in an appropriate manner in one or more embodiments or examples. Furthermore, if not in conflict with each other, a person skilled in the art can combine different embodiments or examples and features of different embodiments or examples described in the present specification.
[0173] Although the embodiments of the present invention have been presented and described, the above embodiments are illustrative and cannot be understood as limiting the present invention, and it will be understood by those skilled in the art that various changes, modifications, substitutions and variations of the above embodiments are possible within the scope of the present invention.
[0174] This application claims priority to and benefits from a Chinese patent application bearing application number 202111485404.0, filed with the China Intellectual Property Office on December 7, 2021, the entire contents of which are hereby incorporated by reference into this application.
Claims
1. A recombinant antibody comprising: CD3 antibody variable region CDR sequences: SEQ ID NO: 1-6, and A recombinant antibody comprising a CDR sequence selected from at least one of B7H6 antibody variable region CDR sequences: SEQ ID NOs: 7 to 12, or an amino acid sequence having at least 95% identity thereto.
2. The recombinant antibody of claim 1, characterized in that it comprises a variable region of a CD3 antibody, the variable region of the CD3 antibody having an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to a light chain variable region shown in SEQ ID NO: 13 and a heavy chain variable region shown in SEQ ID NO: 14, or to the amino acid sequences shown in SEQ ID NO: 13 and SEQ ID NO:
14.
3. The antibody comprises a variable region of the B7H6 antibody, the variable region of the B7H6 antibody having an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a light chain variable region having an amino acid sequence as set forth in SEQ ID NO: 20 and a heavy chain variable region having an amino acid sequence as set forth in SEQ ID NO: 23, or to the amino acid sequences as set forth in SEQ ID NO: 20 and SEQ ID NO: 23; The variable region of the B7H6 antibody has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a light chain variable region having an amino acid sequence shown in SEQ ID NO: 16 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO: 22, or to the amino acid sequences shown in SEQ ID NO: 16 and SEQ ID NO: 22; The variable region of the B7H6 antibody has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a light chain variable region having an amino acid sequence shown in SEQ ID NO: 16 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO: 23, or to the amino acid sequences shown in SEQ ID NO: 16 and SEQ ID NO: 23; The variable region of the B7H6 antibody has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a light chain variable region having an amino acid sequence shown in SEQ ID NO: 16 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO: 24, or to the amino acid sequences shown in SEQ ID NO: 16 and SEQ ID NO: 24; The variable region of the B7H6 antibody has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a light chain variable region having an amino acid sequence shown in SEQ ID NO: 16 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO: 25, or to the amino acid sequences shown in SEQ ID NO: 16 and SEQ ID NO: 25; The variable region of the B7H6 antibody has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a light chain variable region having an amino acid sequence shown in SEQ ID NO: 17 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO: 22, or to the amino acid sequences shown in SEQ ID NO: 17 and SEQ ID NO: 22; The variable region of the B7H6 antibody has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a light chain variable region having an amino acid sequence shown in SEQ ID NO: 17 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO: 23, or to the amino acid sequences shown in SEQ ID NO: 17 and SEQ ID NO: 23; The variable region of the B7H6 antibody has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a light chain variable region having an amino acid sequence shown in SEQ ID NO: 17 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO: 24, or to the amino acid sequences shown in SEQ ID NO: 17 and SEQ ID NO: 24; The variable region of the B7H6 antibody has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a light chain variable region having an amino acid sequence shown in SEQ ID NO: 17 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO: 25, or to the amino acid sequences shown in SEQ ID NO: 17 and SEQ ID NO: 25; The variable region of the B7H6 antibody has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a light chain variable region having an amino acid sequence shown in SEQ ID NO: 19 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO: 22, or to the amino acid sequences shown in SEQ ID NO: 19 and SEQ ID NO: 22; The variable region of the B7H6 antibody has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a light chain variable region having an amino acid sequence shown in SEQ ID NO: 19 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO: 23, or to the amino acid sequences shown in SEQ ID NO: 19 and SEQ ID NO: 23; The variable region of the B7H6 antibody has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a light chain variable region having an amino acid sequence shown in SEQ ID NO: 19 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO: 24, or to the amino acid sequences shown in SEQ ID NO: 19 and SEQ ID NO: 24; The variable region of the B7H6 antibody has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a light chain variable region having an amino acid sequence shown in SEQ ID NO: 19 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO: 25, or an amino acid sequence shown in SEQ ID NO: 19 and SEQ ID NO: 25; The variable region of the B7H6 antibody has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a light chain variable region having an amino acid sequence shown in SEQ ID NO: 20 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO: 22, or to the amino acid sequences shown in SEQ ID NO: 20 and SEQ ID NO: 22; The variable region of the B7H6 antibody has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a light chain variable region having an amino acid sequence shown in SEQ ID NO: 20 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO: 24, or to the amino acid sequences shown in SEQ ID NO: 20 and SEQ ID NO: 24; The variable region of the B7H6 antibody has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a light chain variable region having an amino acid sequence shown in SEQ ID NO: 20 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO: 25, or an amino acid sequence having an amino acid sequence shown in SEQ ID NO: 20 and SEQ ID NO: 25; The variable region of the B7H6 antibody has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a light chain variable region having an amino acid sequence shown in SEQ ID NO: 15 and a heavy chain variable region having an amino acid sequence shown in SEQ ID NO: 26, or to the amino acid sequences shown in SEQ ID NO: 15 and SEQ ID NO: 26; The recombinant antibody of claim 1, characterized in that the variable region of the B7H6 antibody has an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identity to a light chain variable region having the amino acid sequence shown in SEQ ID NO: 18 and a heavy chain variable region having the amino acid sequence shown in SEQ ID NO: 21, or to the amino acid sequences shown in SEQ ID NO: 18 and SEQ ID NO:
21.
4. further comprising a connecting peptide, Optionally, the connecting peptide has the amino acid sequence shown in SEQ ID NO:
46. The recombinant antibody of claim 1.
5. The recombinant antibody of claim 4, wherein the N-terminus of the connecting peptide is linked to the C-terminus of the CD3 antibody light chain variable region and the C-terminus of the connecting peptide is linked to the N-terminus of the CD3 antibody heavy chain variable region.
6. The recombinant antibody of claim 4, wherein the N-terminus of the connecting peptide is linked to the C-terminus of the B7H6 light chain variable region and the C-terminus of the connecting peptide is linked to the N-terminus of the B7H6 heavy chain variable region.
7. The recombinant antibody described in claim 1, further comprising a first Fc region and a second Fc region, wherein at least a portion of the first Fc region and the second Fc region are derived from at least one of a mouse-derived antibody, a human-derived antibody, a primate-derived antibody or a variant thereof.
8. At least a portion of the first Fc region and the second Fc region is derived from a human IgG or a variant thereof; 8. The recombinant antibody of claim 7, wherein optionally, at least a portion of the first Fc region and the second Fc region are derived from human IgG1 or a variant thereof.
9. The recombinant antibody of claim 7, wherein the first Fc region has at least one of an S384C mutation and a T396W mutation compared to a wild-type IgG1 Fc region.
10. The recombinant antibody according to claim 9, characterized in that the second Fc region has at least one of a Y380C mutation, a T397S mutation, a L399A mutation and a Y408V mutation compared to a wild-type IgG1 Fc region.
11. The recombinant antibody according to any one of claims 7 to 10, wherein the first antibody Fc region has the amino acid sequence shown in SEQ ID NO: 47, and the second antibody Fc region has the amino acid sequence shown in SEQ ID NO:
48.
12. A recombinant antibody characterized by having the amino acid sequence shown in SEQ ID NO: 49 and 63.
13. A nucleic acid encoding a recombinant antibody according to any one of claims 1 to 12.
14. 14. The nucleic acid of claim 13, having at least one of the nucleotide sequences set forth in SEQ ID NO: 69 and SEQ ID NO: 70-87.
15. An expression vector, characterized in that it carries the nucleic acid molecule according to claim 13 or 14.
16. A recombinant cell, characterized in that it carries a nucleic acid molecule according to claim 13 or 14, an expression vector according to claim 15 or a recombinant antibody according to any one of claims 1 to 12.
17. A composition comprising a recombinant antibody according to any one of claims 1 to 12, a nucleic acid molecule according to claim 13 or 14, an expression vector according to claim 15 or a recombinant cell according to claim 16.
18. Use of a recombinant antibody according to any one of claims 1 to 12, a nucleic acid molecule according to claim 13 or 14, an expression vector according to claim 15, a recombinant cell according to claim 16 or a composition according to claim 17 in the preparation of a medicament for treating and preventing cancer.
19. 20. The use according to claim 18, characterized in that the cancer comprises at least one of colon cancer, non-small cell lung cancer, breast cancer and liver cancer.
20. A drug comprising a recombinant antibody according to any one of claims 1 to 12, a nucleic acid molecule according to claim 13 or 14, an expression vector according to claim 15, a recombinant cell according to claim 16 or a composition according to claim 17, the drug being used for the treatment and prevention of cancer.
21. The drug of claim 20, wherein the cancer includes at least one of colon cancer, non-small cell lung cancer, breast cancer, and liver cancer.
22. A kit comprising the recombinant antibody according to any one of claims 1 to 12. The kit of claim 20, wherein the kit is used to diagnose at least one of colon cancer, non-small cell lung cancer, breast cancer, and liver cancer.
23. Use of a recombinant antibody according to any one of claims 1 to 12, a nucleic acid molecule according to claim 13 or 14, an expression vector according to claim 15, a recombinant cell according to claim 16, a composition according to claim 17 or a drug according to any one of claims 21 to 22 in the treatment or prevention of cancer.
24. 25. The use according to claim 24, wherein the cancer comprises at least one of colon cancer, non-small cell lung cancer, breast cancer and liver cancer.
25. Subjects were asked, 1) A recombinant antibody according to any one of claims 1 to 12, 2) A nucleic acid molecule according to claim 13 or 14, 3) The expression vector according to claim 15. 4) The recombinant cell according to claim 16. 5) A composition according to claim 17, or 6) A method for the treatment or prevention of cancer, comprising the step of administering at least one of the drugs according to any one of claims 21-22.
26. 27. The method of claim 26, wherein the cancer comprises at least one of colon cancer, non-small cell lung cancer, breast cancer, and liver cancer.
Citation Information
Patent Citations
Anti-B7-H6 antibody, fusion protein, and method for using these.
JP2015519337A
High affinity b7-h6 antibodies and antibody fragments
WO2017181001A1
Multi-specific binding proteins for cancer treatment
WO2021064137A2
